Damir Vareslija

List of Publications by Year
in descending order

29 papers	**741** citations

687363
13 h-index

677142
22 g-index

31 all docs	**31** docs citations

31 times ranked

1495 citing authors

#	Article	IF	Citations
1	Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. Nature Communications, 2022, 13, 514.	12.8	38
2	A clinically compatible drug–screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. EMBO Molecular Medicine, 2022, 14, e14552.	6.9	12
3	Dexamethasone promotes breast cancer stem cells in obese and not lean mice. Pharmacology Research and Perspectives, 2022, 10, e00923.	2.4	3
4	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. Nature Medicine, 2022, 28, 752-765.	30.7	30
5	Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype. Oncogene, 2021, 40, 1318-1331.	5.9	10
6	Abstract PD13-01: Homologous recombination deficiency represents a new therapeutic strategy for breast cancer brain metastases. , 2021, , .		0
7	6-Hydroxydopamine: a far from simple neurotoxin. Journal of Neural Transmission, 2020, 127, 213-230.	2.8	32
8	52. BrMPANEL: A PUBLIC RESOURCE OF ORGANOTROPIC CELL LINES. Neuro-Oncology Advances, 2020, 2, ii10-ii11.	0.7	0
9	ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis. BMC Medicine, 2020, 18, 349.	5.5	8
10	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. Cancer Research, 2020, 80, 4314-4323.	0.9	51
11	FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nature Protocols, 2020, 15, 2503-2518.	12.0	20
12	Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. Journal of the National Cancer Institute, 2019, 111, 388-398.	6.3	81
13	BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer. Clinical Cancer Research, 2019, 25, 7139-7150.	7.0	18
14	Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy. Molecular Cancer Therapeutics, 2019, 18, 1731-1743.	4.1	8
15	A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival. Scientific Reports, 2019, 9, 18518.	3.3	14
16	Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer. Oncogene, 2018, 37, 2008-2021.	5.9	23
17	Epigenome-wide SRC-1–Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 3692-3703.	7.0	13
18	Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers. Journal of Molecular Medicine, 2018, 96, 1025-1037.	3.9	9

#	Article	IF	Citations
19	Intrinsic Subtype Switching and Acquired <i>ERBB2</i>/<i>HER2</i> Amplifications and Mutations in Breast Cancer Brain Metastases. JAMA Oncology, 2017, 3, 666.	7.1	135
20	Patient-Derived Xenografts of Breast Cancer. Methods in Molecular Biology, 2017, 1501, 327-336.	0.9	14
21	Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors. Clinical Cancer Research, 2016, 22, 2765-2777.	7.0	23
22	Abstract 861: Global transcription factor repression by the coactivator SRC-1 mediates disease progression in endocrine-resistant breast cancer. , 2016, , .		0
23	Abstract 3557: System-based BCL2 family protein signatures as predictive biomarkers in triple-negative breast cancer. , 2016, , .		0
24	Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy. Clinical Cancer Research, 2015, 21, 5371-5379.	7.0	25
25	Abstract P3-05-24: Adaptation to AI therapy in breast cancer can induce dynamic alterations in ER activity resulting in estrogen independent metastatic tumours. , 2015, , .		0
26	Abstract P1-07-26: Global analysis of the transcriptome in matched primary and metastatic tumours defines ER specific gene alterations. , 2015, , .		0
27	Abstract P3-05-02: Global characterisation of the SRC-1 transcriptome and rational drug design results in the identification of a novel peptide targeting ADAM22 in endocrine resistance. , 2015, , .		0
28	AIB1:ERÎ± Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitorâ€"Resistant Breast Cancer Cells. Clinical Cancer Research, 2012, 18, 3305-3315.	7.0	41
29	Highly reactive oxygen species: detection, formation, and possible functions. Cellular and Molecular Life Sciences, 2011, 68, 2067-2079.	5.4	133